MA38135A2 - Dérivés d'oxazolidinone 3,4-disubstituée et leur utilisation comme inhibiteurs des canaux potassiques activés par le calcium - Google Patents
Dérivés d'oxazolidinone 3,4-disubstituée et leur utilisation comme inhibiteurs des canaux potassiques activés par le calciumInfo
- Publication number
- MA38135A2 MA38135A2 MA38135A MA38135A MA38135A2 MA 38135 A2 MA38135 A2 MA 38135A2 MA 38135 A MA38135 A MA 38135A MA 38135 A MA38135 A MA 38135A MA 38135 A2 MA38135 A2 MA 38135A2
- Authority
- MA
- Morocco
- Prior art keywords
- calcium
- potassium channel
- channel inhibitors
- activated potassium
- oxazolidinone derivatives
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
- C07D263/20—Oxygen atoms attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Epidemiology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
L'invention porte sur des composés représentés par la formule générale i, dans laquelle n, r1, r2a, r2b, r3a et r3b sont tels que définis dans la description, sur des compositions comprenant les composés et sur des procédés d'utilisation des composés.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12190319 | 2012-10-29 | ||
PCT/EP2013/072361 WO2014067861A1 (fr) | 2012-10-29 | 2013-10-25 | Dérivés d'oxazolidinone 3,4-disubstituée et leur utilisation comme inhibiteurs des canaux potassiques activés par le calcium |
Publications (2)
Publication Number | Publication Date |
---|---|
MA38135A2 true MA38135A2 (fr) | 2016-11-30 |
MA38135B1 MA38135B1 (fr) | 2018-11-30 |
Family
ID=47143594
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA38135A MA38135B1 (fr) | 2012-10-29 | 2013-10-25 | Dérivés d'oxazolidinone 3,4-disubstituée et leur utilisation comme inhibiteurs des canaux potassiques activés par le calcium |
Country Status (24)
Country | Link |
---|---|
US (1) | US9611232B2 (fr) |
EP (1) | EP2912034B1 (fr) |
JP (1) | JP6216385B2 (fr) |
KR (1) | KR20150075091A (fr) |
CN (1) | CN104781256B (fr) |
AR (1) | AR093168A1 (fr) |
AU (1) | AU2013339607A1 (fr) |
BR (1) | BR112015003996A2 (fr) |
CA (1) | CA2879249A1 (fr) |
CL (1) | CL2015000906A1 (fr) |
CO (1) | CO7170170A2 (fr) |
CR (1) | CR20150159A (fr) |
EA (1) | EA026161B1 (fr) |
HK (1) | HK1207632A1 (fr) |
IL (1) | IL237331A0 (fr) |
IN (1) | IN2015DN00961A (fr) |
MA (1) | MA38135B1 (fr) |
MX (1) | MX2015002399A (fr) |
PE (1) | PE20150775A1 (fr) |
PH (1) | PH12015500292A1 (fr) |
SG (1) | SG11201500585XA (fr) |
TW (1) | TW201422596A (fr) |
UA (1) | UA114649C2 (fr) |
WO (1) | WO2014067861A1 (fr) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102047502B1 (ko) * | 2016-06-20 | 2019-11-22 | 셀라이온바이오메드 주식회사 | 포타슘 채널 단백질을 이용한 암 진단용 조성물 |
EP3941903A1 (fr) | 2019-03-22 | 2022-01-26 | Saniona A/S | Nouveaux inhibiteurs des canaux potassiques |
JP2023544520A (ja) | 2020-09-22 | 2023-10-24 | サニオナ エー/エス | 新規カリウムチャネル阻害剤 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2538424C2 (de) * | 1975-08-29 | 1983-01-05 | Nordmark-Werke Gmbh, 2000 Hamburg | 4-substituierte 5-Phenyl-oxazolidon-(2)- Verbindungen und ein diese enthaltendes pharmazeutisches Präparat |
EP0215435B1 (fr) * | 1985-09-09 | 1993-03-03 | Otsuka Pharmaceutical Co., Ltd. | Dérivés de 2-oxa-isocéphème, compositions les contenant et procédés pour les préparer |
EP0557408A4 (en) * | 1990-11-06 | 1993-10-27 | Smith-Kline Beecham Corporation | Imidazolidinone compounds |
DE4439846A1 (de) * | 1994-11-08 | 1996-05-09 | Merck Patent Gmbh | Adhäsionsrezeptor-Antagonisten |
AU1812197A (en) * | 1996-03-01 | 1997-09-16 | Sankyo Company Limited | Hydroxamic acid derivatives |
EP1144387A1 (fr) * | 1998-12-04 | 2001-10-17 | Neurosearch A/S | Nouveaux derives de benzimidazolone, de benzoxazolone ou de benzothiazolone agissant comme agents de modulation de canaux ioniques |
EP1254895B1 (fr) * | 2000-01-20 | 2007-05-23 | Eisai R&D Management Co., Ltd. | Composes azotes cycliques et compositions pharmaceutiques les contenant |
JP3966693B2 (ja) * | 2000-01-20 | 2007-08-29 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 含窒素環化合物およびそれらを含んでなる医薬組成物 |
US6903089B1 (en) * | 2000-11-22 | 2005-06-07 | Bayer Aktiengesellschaft | Lactam-substituted pyrazolopyridine derivatives |
US7879839B2 (en) | 2004-07-29 | 2011-02-01 | Merck Sharp & Dohme Corp. | Potassium channel inhibitors |
DE102004060229A1 (de) * | 2004-12-15 | 2006-06-29 | Sanofi-Aventis Deutschland Gmbh | Neue zyklische Harnstoffe als Inhibitoren von Metallproteasen |
US7378530B2 (en) * | 2005-02-22 | 2008-05-27 | Nereus Pharmaceuticals, Inc. | Anti-cancer and anti-microbial 5-membered heterocyclic compounds |
US20100056637A1 (en) | 2005-12-20 | 2010-03-04 | Icagen, Inc. | Treatment methods using triaryl methane compounds |
WO2007109098A2 (fr) * | 2006-03-16 | 2007-09-27 | Azevan Pharmaceuticals, Inc. | ACIDES β-LACTAMYL ALCANEDIOÏQUES HYDROXY OU CÉTO-SUBSTITUÉS |
AR074558A1 (es) * | 2008-12-12 | 2011-01-26 | Solvay Pharm Bv | Espiro azepan oxazolidinonas como bloqueadores del canal de potasio kv1.3 |
WO2010123997A1 (fr) * | 2009-04-22 | 2010-10-28 | Achaogen, Inc. | Antibiotiques bêta-lactames carbacéphèmes |
-
2013
- 2013-10-25 KR KR1020157011024A patent/KR20150075091A/ko not_active Application Discontinuation
- 2013-10-25 IN IN961DEN2015 patent/IN2015DN00961A/en unknown
- 2013-10-25 JP JP2015538458A patent/JP6216385B2/ja not_active Expired - Fee Related
- 2013-10-25 EA EA201590729A patent/EA026161B1/ru not_active IP Right Cessation
- 2013-10-25 PE PE2015000296A patent/PE20150775A1/es not_active Application Discontinuation
- 2013-10-25 MA MA38135A patent/MA38135B1/fr unknown
- 2013-10-25 EP EP13783333.1A patent/EP2912034B1/fr not_active Not-in-force
- 2013-10-25 AU AU2013339607A patent/AU2013339607A1/en not_active Abandoned
- 2013-10-25 CN CN201380056503.4A patent/CN104781256B/zh not_active Expired - Fee Related
- 2013-10-25 WO PCT/EP2013/072361 patent/WO2014067861A1/fr active Application Filing
- 2013-10-25 UA UAA201504977A patent/UA114649C2/uk unknown
- 2013-10-25 SG SG11201500585XA patent/SG11201500585XA/en unknown
- 2013-10-25 MX MX2015002399A patent/MX2015002399A/es unknown
- 2013-10-25 BR BR112015003996A patent/BR112015003996A2/pt not_active IP Right Cessation
- 2013-10-25 CA CA2879249A patent/CA2879249A1/fr not_active Abandoned
- 2013-10-28 AR ARP130103922A patent/AR093168A1/es unknown
- 2013-10-28 TW TW102138950A patent/TW201422596A/zh unknown
-
2015
- 2015-01-16 CO CO15008510A patent/CO7170170A2/es unknown
- 2015-02-10 PH PH12015500292A patent/PH12015500292A1/en unknown
- 2015-02-19 IL IL237331A patent/IL237331A0/en unknown
- 2015-03-20 CR CR20150159A patent/CR20150159A/es unknown
- 2015-04-10 CL CL2015000906A patent/CL2015000906A1/es unknown
- 2015-04-29 US US14/699,144 patent/US9611232B2/en not_active Expired - Fee Related
- 2015-08-25 HK HK15108258.3A patent/HK1207632A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
US9611232B2 (en) | 2017-04-04 |
TW201422596A (zh) | 2014-06-16 |
PE20150775A1 (es) | 2015-05-21 |
CN104781256B (zh) | 2017-09-29 |
IN2015DN00961A (fr) | 2015-06-12 |
SG11201500585XA (en) | 2015-04-29 |
HK1207632A1 (en) | 2016-02-05 |
CA2879249A1 (fr) | 2014-05-08 |
PH12015500292A1 (en) | 2015-04-20 |
JP6216385B2 (ja) | 2017-10-18 |
IL237331A0 (en) | 2015-04-30 |
BR112015003996A2 (pt) | 2017-07-04 |
MA38135B1 (fr) | 2018-11-30 |
KR20150075091A (ko) | 2015-07-02 |
EA201590729A1 (ru) | 2015-07-30 |
US20150246894A1 (en) | 2015-09-03 |
MX2015002399A (es) | 2015-06-10 |
AR093168A1 (es) | 2015-05-20 |
EA026161B1 (ru) | 2017-03-31 |
CN104781256A (zh) | 2015-07-15 |
AU2013339607A1 (en) | 2015-02-05 |
CO7170170A2 (es) | 2015-01-28 |
EP2912034A1 (fr) | 2015-09-02 |
WO2014067861A1 (fr) | 2014-05-08 |
UA114649C2 (uk) | 2017-07-10 |
JP2015535231A (ja) | 2015-12-10 |
EP2912034B1 (fr) | 2017-05-31 |
CL2015000906A1 (es) | 2015-09-11 |
CR20150159A (es) | 2015-04-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA37756A1 (fr) | Nouveaux composés diazaspirocycloalcane et azaspirocycloalcane | |
MY155317A (en) | Benzene sulfonamide thiazole and oxazole compounds | |
ES2571489T3 (es) | Producto cosmético sólido para labios | |
CL2017002283A1 (es) | Formulaciones de anticuerpos y métodos (divisional de solicitud n°1081-2014) | |
UY33750A (es) | ?Compuestos insecticidas aromáticos derivados de bisamida, procesos e intermediarios para prepararlos y composiciones que los usan.? | |
GEP20166432B (en) | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh | |
PH12014502169A1 (en) | N-cyclylamides as nematicides | |
GEP20166474B (en) | Pyrazolospiroketone derivatives for use as acetyl-coa carboxylase inhibitors | |
MA38826B1 (fr) | Nouveaux dérivés de triazolo[4,5-d]pyrimidine | |
MA33939B1 (fr) | 5-alcynyl-pyrimidines | |
WO2018136437A3 (fr) | Nouveaux composés utiles en tant qu'inhibteurs de l'indoléamine 2,3-dioxygénase et/ou du tryptophane dioxygénase | |
MA35663B1 (fr) | Dérivés de [1, 2, 3]triazolo [4, 5 -d] pyrimidine comme agonistes des récepteurs aux cannabinoïdes 2 | |
MA34652B1 (fr) | Hétéroaryles et utilisations de ceux-ci | |
UY34413A (es) | Formulaciones, composiciones, metabolitos de chro mobacterium y sus usos | |
MY169267A (en) | New aryl-quinoline derivatives | |
UA106880C2 (uk) | Нові гербіциди | |
GEP20156315B (en) | Oxazoline and isoxazoline derivatives as crac modulators | |
MA35816B1 (fr) | Dérivés d'aniline, leur préparation et leur application thérapeutique | |
MX358429B (es) | Nuevos derivados de isocromano e isotiocromano agonistas del adrenoreceptor alfa2a, especialmente agonistas del adrenoreceptor alfa2a para usarse como sedantes o analgesicos. | |
CR20130106A (es) | Nuevos moduladores de trpv3 | |
MA38135A2 (fr) | Dérivés d'oxazolidinone 3,4-disubstituée et leur utilisation comme inhibiteurs des canaux potassiques activés par le calcium | |
WO2013081778A3 (fr) | Composés nitrones et leur utilisation dans le soin personnel | |
TN2009000536A1 (en) | Novel herbicides | |
MA32985B1 (fr) | Nouveaux microbiocides | |
EP2590652A4 (fr) | Compositions pharmaceutiques contenant de la vanoxérine |